These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15236622)

  • 1. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
    Duval X; Peytavin G; Albert I; Bénoliel S; Ecobichon JL; Brun-Vézinet F; Mentré F; Leport C; Vildé JL
    HIV Med; 2004 Jul; 5(4):307-13. PubMed ID: 15236622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.
    Urban AW; Bean P; Aziz D; Graziano FM; Neudeck BL
    Int J STD AIDS; 2003 Feb; 14(2):103-8. PubMed ID: 12662388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
    HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
    BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Baroncelli S; Villani P; Floridia M; Pirillo MF; Galluzzo CM; Cusato M; Amici R; Pinnetti C; Sabbatini F; Molinari A; Tamburrini E; Regazzi M
    Ther Drug Monit; 2008 Oct; 30(5):604-10. PubMed ID: 18728627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients.
    Wateba MI; Billaud E; Dailly E; Jolliet P; Raffi F
    HIV Med; 2006 Apr; 7(3):197-9. PubMed ID: 16494635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
    Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
    Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
    Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V; Hocht C; Mangano A; Niselman V; Mariño Hernández E; Cáceres Guido P; Mecikovsky D; Bellusci C; Bologna R; Sen L; Rubio MC; Bramuglia GF
    Pharmacology; 2009; 83(1):59-66. PubMed ID: 19052483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
    Karlström O; Ståhle L; Perrin L; Tegude H; Sönnerborg A
    Scand J Infect Dis; 2006; 38(5):371-4. PubMed ID: 16709540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
    Gatti G; Castelli-Gattinara G; Cruciani M; Bernardi S; De Pascalis CR; Pontali E; Papa L; Miletich F; Bassetti D
    Clin Infect Dis; 2003 Jun; 36(11):1476-82. PubMed ID: 12766843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
    Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
    Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
    Descamps D; Joly V; Flandre P; Peytavin G; Meiffrédy V; Delarue S; Lastère S; Aboulker JP; Yeni P; Brun-Vézinet F
    J Clin Virol; 2005 Jun; 33(2):99-103. PubMed ID: 15911424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
    Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C
    HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
    Wasmuth JC; Rodermann E; Voigt E; Vogel M; Lauenroth-Mai E; Jessen A; Burger D; Rockstroh JK
    Eur J Med Res; 2007 Jul; 12(7):289-94. PubMed ID: 17933700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
    Danel C; Moh R; Peytavin G; Anzian A; Minga A; Gomis OB; Seri B; Nzunettu G; Gabillard D; Salamon R; Bissagnene E; Anglaret X
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):62-6. PubMed ID: 17263634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
    Riddler SA; Havlir D; Squires KE; Kerr B; Lewis RH; Yeh K; Wynne LH; Zhong L; Peng Y; Deutsch P; Saah A
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3877-82. PubMed ID: 12435691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.